TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35654052

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax (ibrutinib: 420 mg once daily; venetoclax: weekly ramp-up from 20 mg to 400 mg once daily)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ibrutinib maintenance
Number of subjects: 225

Group type: COMPARATOR
Intervention: Treatment cessation
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ibrutinib monotherapy (for patients not randomly assigned)
Number of subjects: 225
Study: 32019598

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous paracetamol
Number of subjects: 20
Study: 36314570

Group type: EXPERIMENTAL
Intervention: Forced Awakening (FA)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Undisturbed Sleep (US)
Number of subjects: 95
Study: 33130949

Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern
Number of subjects: 35175

Group type: EXPERIMENTAL
Intervention: Animal food dietary pattern
Number of subjects: 35175

Group type: EXPERIMENTAL
Intervention: Sweet dietary pattern
Number of subjects: 35175
Study: 33228006

Group type: EXPERIMENTAL
Intervention: Any intervention arm
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 234
Study: 35767384

Group type: EXPERIMENTAL
Intervention: Remestemcel-L (150 million MSCs)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 34177385

Group type: EXPERIMENTAL
Intervention: 5-week at-home positive psychology intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 30
Study: 33368307

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tezepelumab doses up to 280 mg every 2 weeks
Number of subjects: 0
Study: 32861841

Group type: EXPERIMENTAL
Intervention: Family-focused therapy
Number of subjects: 126
Study: 36091030

Group type: COMPARATOR
Intervention: Celecoxib 200 mg bid
Number of subjects: 150

Group type: COMPARATOR
Intervention: Etanercept 50 mg qw
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined therapy (etanercept + celecoxib)
Number of subjects: 150
Study: 34047371

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 101
Study: 32879960

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) programme
Number of subjects: 790
Study: 35766128

Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.5 mg/kg SC
Number of subjects: 70
Study: 33882446

Group type: EXPERIMENTAL
Intervention: Mobile phone app-based training plus routine care for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 34196132

Group type: EXPERIMENTAL
Intervention: MA-Bu regimen
Number of subjects: 224

Group type: COMPARATOR
Intervention: MA-Bu vs. MA-TBI vs. RIST-Bu
Number of subjects: 224

Group type: COMPARATOR
Intervention: MA-Bu vs. MA-TBI
Number of subjects: 224

Group type: COMPARATOR
Intervention: Oral busulfan vs. intravenous busulfan
Number of subjects: 224
Study: 34962561

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin once daily
Number of subjects: 15480

Group type: COMPARATOR
Intervention: Matching placebo for aspirin
Number of subjects: 15480

Group type: EXPERIMENTAL
Intervention: 1 g of ω-3 fatty acids once daily
Number of subjects: 15480

Group type: COMPARATOR
Intervention: Matching placebo for ω-3 fatty acids
Number of subjects: 15480
Study: 36012078

Group type: EXPERIMENTAL
Intervention: ETUCARE online self-help program (n = 53)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control condition (n = 50)
Number of subjects: 103
Study: 32067691

Group type: EXPERIMENTAL
Intervention: 12-month trastuzumab treatment
Number of subjects: 481

Group type: COMPARATOR
Intervention: 6-month trastuzumab treatment
Number of subjects: 481
Study: 36100672

Group type: EXPERIMENTAL
Intervention: Esaxerenone
Number of subjects: 0
Study: 33908288

Group type: EXPERIMENTAL
Intervention: Single structured early palliative care intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 150
Study: 32889373

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33095469

Group type: COMPARATOR
Intervention: FFC-AL-EIT intervention implemented by a function focused care nurse facilitator over 12 months.
Number of subjects: 550

Group type: COMPARATOR
Intervention: FFC-AL-EIT intervention
Number of subjects: 550
Study: 32569024

Group type: EXPERIMENTAL
Intervention: Atypical glandular cell (AGC) Pap tests with abnormal uterine bleeding
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Atypical glandular cell (AGC) Pap tests with HPV positivity
Number of subjects: 478

Group type: COMPARATOR
Intervention: AGC Pap tests
Number of subjects: 478
Study: 35265304

Group type: EXPERIMENTAL
Intervention: Capecitabine sequential treatment for 4 cycles
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no sequential treatment)
Number of subjects: 100
Study: 32100452

Group type: EXPERIMENTAL
Intervention: Sequential boost of intensity-modulated radiation therapy (IMRT) with chemotherapy (fluorouracil 600 mg/m2 days 1-3 and cisplatin 25 mg/m2 days 1-3, every 4 weeks for 4 cycles)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sequential boost of intensity-modulated radiation therapy (IMRT) with chemotherapy
Number of subjects: 88
Study: 36071284

Group type: EXPERIMENTAL
Intervention: Dynamic equilibrium gait training (DEGT) for 6 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard exercise (SE) for 6 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Natural course (NC)
Number of subjects: 70
Study: 34480060

Group type: EXPERIMENTAL
Intervention: Microparticles and PD1 expressions in MM patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients who did not achieve complete response
Number of subjects: 30
Study: 34134521

Group type: EXPERIMENTAL
Intervention: Cradle hold position
Number of subjects: 67

Group type: COMPARATOR
Intervention: Football hold position
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 67
Study: 35863669

Group type: EXPERIMENTAL
Intervention: Prednisolone (0.5mg/kg/day, maximum 40mg/day, for 14±2 days)
Number of subjects: 27
Study: 34459060

Group type: EXPERIMENTAL
Intervention: Sleep-extension programme based on cognitive behavioural principles (n=10)
Number of subjects: 18
Study: 33714568

Group type: EXPERIMENTAL
Intervention: GAC silicone ligatures (in vivo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GAC silicone ligatures (in vitro)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Other ligature groups (in vivo and in vitro)
Number of subjects: 20
Study: 35410445

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training for 16 weeks (32 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 0
Study: 34297360

Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in 1954-1969
Number of subjects: 8886

Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in the 1970s
Number of subjects: 8886

Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in the 1980s
Number of subjects: 8886

Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in the 1990s
Number of subjects: 8886

Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in the 2000s
Number of subjects: 8886

Group type: COMPARATOR
Intervention: General population (control group)
Number of subjects: 8886
Study: 32493552

Group type: EXPERIMENTAL
Intervention: Scopolamine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 0
Study: 35028170

Group type: EXPERIMENTAL
Intervention: Chamomile extract cream
Number of subjects: 73

Group type: COMPARATOR
Intervention: Clotrimazole vaginal cream
Number of subjects: 73
Study: 33022056

Group type: EXPERIMENTAL
Intervention: Nasal Outcome Score for Epistaxis (NOSE HHT)
Number of subjects: 401
Study: 36445843

Group type: EXPERIMENTAL
Intervention: ORSIM (high-fidelity task trainer)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wooden-block (low-fidelity task trainer)
Number of subjects: 24
Study: 33046528

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: laryngeal mask airway
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: endotracheal tube
Number of subjects: 80

Group type: COMPARATOR
Intervention: laryngeal mask airway and i-gel
Number of subjects: 80
Study: 35850871

Group type: EXPERIMENTAL
Intervention: Digital dentures
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 16
Study: 33175143

Group type: EXPERIMENTAL
Intervention: Nomogram based on AJCC T, N stage, bone metastases, brain metastases, and liver metastases as predictors.
Number of subjects: 16059

Group type: EXPERIMENTAL
Intervention: Nomogram including mixed histological types, chemotherapy, and primary site surgery as factors.
Number of subjects: 16059
Study: 35946018

Group type: EXPERIMENTAL
Intervention: Preanesthetic fluid loading with Ringer's lactate (20 mL/kg over 30 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No preloading (2 mL/kg/h maintenance)
Number of subjects: 60
Study: 32805028

Group type: EXPERIMENTAL
Intervention: Avocado consumption (175 g for men; 140 g for women) once daily for 12 weeks
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Avocado consumption
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (no avocado)
Number of subjects: 163
Study: 32693198

Group type: EXPERIMENTAL
Intervention: REAL media program
Number of subjects: 639

Group type: COMPARATOR
Intervention: Control (delayed program use)
Number of subjects: 639
Study: 35524695

Group type: EXPERIMENTAL
Intervention: Daily fortified balanced energy-protein supplement and an iron-folic acid (IFA) tablet
Number of subjects: 1757

Group type: COMPARATOR
Intervention: IFA tablet only
Number of subjects: 1757
Study: 33650326

Group type: EXPERIMENTAL
Intervention: Robot-assisted vitreoretinal surgery
Number of subjects: 8

Group type: COMPARATOR
Intervention: Manual surgery
Number of subjects: 8
Study: 32917847

Group type: EXPERIMENTAL
Intervention: PEEP (Positive End-Expiratory Pressure)
Number of subjects: 417

Group type: COMPARATOR
Intervention: No PEEP (Control)
Number of subjects: 417
Study: 34068687

Group type: EXPERIMENTAL
Intervention: Low-Calorie Diet (LCD) 800 kcal/day for 8 weeks
Number of subjects: 782
Study: 34147829

Group type: EXPERIMENTAL
Intervention: Hybrid ASC-ICO algorithm
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Hybrid BA-ICO algorithm
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standalone ICO algorithm
Number of subjects: 244

Group type: COMPARATOR
Intervention: Hybrid AR-ICO algorithm
Number of subjects: 244
Study: 33256337

Group type: EXPERIMENTAL
Intervention: Changsulin®
Number of subjects: 578

Group type: COMPARATOR
Intervention: Lantus®
Number of subjects: 578
Study: 35672586

Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition (EEN)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 47
Study: 33523106

Group type: EXPERIMENTAL
Intervention: AA:DHA supplementation (100 mg/kg/d of AA and 50 mg/kg/d of DHA)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: AA:DHA supplementation
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 206
Study: 34269503

Group type: EXPERIMENTAL
Intervention: NC + 5% HNa + 1% Gln
Number of subjects: 40

Group type: COMPARATOR
Intervention: NC
Number of subjects: 40
Study: 35765137

Group type: EXPERIMENTAL
Intervention: Pain drawings interpretation by clinicians
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Inter-clinician agreement
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Topographic pain frequency maps
Number of subjects: 98
Study: 33389189

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg 2 hours before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAP block with 60 mL 0.25% levobupivacaine after general anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg 2 hours before surgery and 50 mg rectal diclofenac sodium on recovery from general anesthesia
Number of subjects: 60
Study: 35869503

Group type: EXPERIMENTAL
Intervention: automated, theory‐informed text messages daily for 12 months plus endowment incentives linked to verified weight loss targets at 3, 6 and 12 months
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: the same text messages and weight loss assessment protocol
Number of subjects: 585

Group type: COMPARATOR
Intervention: 12 month waiting list, then text messages for 3 months
Number of subjects: 585
Study: 34175558

Group type: EXPERIMENTAL
Intervention: 30% HRR exercise
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 50% HRR exercise
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 70% HRR exercise
Number of subjects: 83
Study: 34016024

Group type: EXPERIMENTAL
Intervention: Low-load/high-repetition resistance training (LL/HR)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-load/low-repetition resistance training (HL/LR)
Number of subjects: 31
Study: 34656640

Group type: EXPERIMENTAL
Intervention: BIA-guided volume management
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 U weekly for 8 weeks followed by 10,000 U weekly for 44 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 34444963

Group type: EXPERIMENTAL
Intervention: 688 mg/day palmiteolate (omega-7 fatty acid supplementation)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Medium-chain triglycerides (placebo)
Number of subjects: 56
Study: 35104737

Group type: EXPERIMENTAL
Intervention: 10 mg donepezil hydrochloride (test formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg donepezil hydrochloride (reference formulation)
Number of subjects: 0
Study: 33218514

Group type: EXPERIMENTAL
Intervention: CV4 technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 90
Study: 35001501

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg tablet once daily, switched from Efavirenz (EFV) plus two NRTIs for ≥3 months
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg tablet once daily
Number of subjects: 102
Study: 34357729

Group type: EXPERIMENTAL
Intervention: Passive self-ligation braces, Pitts Broad, and early short elastics
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ligature braces and archwires Orthos
Number of subjects: 46
Study: 34913149

Group type: EXPERIMENTAL
Intervention: Jiuwei Zhuhuang Powder (JWZH) 1 to 1.5 g, twice to thrice daily for 5 days
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional treatment (Pediatric Paracetamol, Artificial Cow‐bezoar and Chlorphenamine Maleate Granules, 0.25 to 1 g, thrice daily for 5 days)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Jiuwei Zhuhuang Powder (JWZH)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional treatment (Pediatric Paracetamol, Artificial Cow‐bezoar and Chlorphenamine Maleate Granules)
Number of subjects: 142
Study: 32600260

Group type: EXPERIMENTAL
Intervention: Standard syphilis self-testing arm
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Self-testing arm enhanced with crowdsourcing and a lottery-based incentive
Number of subjects: 444

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 444
Study: 34688773

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 34
Study: 32271690

Group type: EXPERIMENTAL
Intervention: Robotic radical cystectomy
Number of subjects: 302

Group type: COMPARATOR
Intervention: Open radical cystectomy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Continent diversion
Number of subjects: 302

Group type: COMPARATOR
Intervention: Noncontinent diversion
Number of subjects: 302
Study: 616659783

Group type: EXPERIMENTAL
Intervention: Controlled diet plan given by a nutritionist
Number of subjects: 244

Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 244
Study: 34553256

Group type: EXPERIMENTAL
Intervention: Deep-learning model for identifying fresh VCFs from digital radiography (DR)
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Lateral views of DR
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Grade 3 VCF subgroup
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Crush-type VCF subgroup
Number of subjects: 1099
Study: 32470089

Group type: EXPERIMENTAL
Intervention: Standard cash incentive (US$4)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Commitment contract (low- or high-value deposit returned with interest upon retesting)
Number of subjects: 130

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 130
Study: 36064428

Group type: EXPERIMENTAL
Intervention: Growth Assessment Protocol (GAP)
Number of subjects: 13
Study: 32459670

Group type: EXPERIMENTAL
Intervention: Kinesiotaping and Lymphatic drainage Group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lymphatic drainage Group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Kinesiotaping Group
Number of subjects: 99
Study: 34612802

Group type: EXPERIMENTAL
Intervention: Clinical meditation and imagery (CMI) intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (education on health and function after SCI)
Number of subjects: 24
Study: 33813585

Group type: EXPERIMENTAL
Intervention: High-concentration phospholipid eye spray (Tears Again)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-concentration phospholipid eye spray (Ocuvers)
Number of subjects: 30
Study: 35629004

Group type: EXPERIMENTAL
Intervention: 5-week serious game-based auditory training (AT) program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 34039773

Group type: EXPERIMENTAL
Intervention: Lègong dance training (DG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerobic training (AG)
Number of subjects: 40
Study: 36089810

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Empagliflozin + Losartan
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34418224

Group type: EXPERIMENTAL
Intervention: Anonymous participation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Confidential participation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Confidential participation with consent for collection of register data
Number of subjects: 0
Study: 32739652

Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy for 9 months
Number of subjects: 7700

Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel for 9 months followed by aspirin monotherapy for 3 months
Number of subjects: 7700
Study: 34044526

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 0.5 mg/mL combined with triamcinolone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 5.0 mg/mL combined with triamcinolone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil at 12.5 mg/mL combined with triamcinolone
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study: 33121503

Group type: EXPERIMENTAL
Intervention: FTC‐TDF or FTC‐TAF (over 1 or 2 days, with final dose given either 6 or 20 hours prior to surgery)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No PrEP prior to surgery
Number of subjects: 144
Study: 33852247

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study: 33259621

Group type: EXPERIMENTAL
Intervention: Multistrategic, community-wide interventions using social marketing techniques and network intervention (e.g., word of mouth) over 5 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous studies with interventions lasting 1 to 3 years
Number of subjects: 0
Study: 35556389

Group type: EXPERIMENTAL
Intervention: 2-week lithium treatment (40 mmol/kg/food)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 4-week lithium treatment (40 mmol/kg/food)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo group from previous trial
Number of subjects: 9
Study: 33007353

Group type: EXPERIMENTAL
Intervention: Patiromer (starting doses ranged from 8.4 to 33.6 g/day)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Patiromer (safety outcomes)
Number of subjects: 653
Study: 33949680

Group type: EXPERIMENTAL
Intervention: Written communication via leaflet with visual aids (L-VA)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Written communication via leaflet with no visual aids (L-NVA)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Only verbal communication with no leaflet (NL)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Health belief model constructs
Number of subjects: 99
Study: 34600178

Group type: EXPERIMENTAL
Intervention: Low-load plyometric running intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 32873311

Group type: EXPERIMENTAL
Intervention: Women living with HIV
Number of subjects: 1693

Group type: COMPARATOR
Intervention: Women not living with HIV
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Women living with HIV (currently breastfeeding)
Number of subjects: 1693

Group type: COMPARATOR
Intervention: Women not living with HIV (currently breastfeeding)
Number of subjects: 1693
Study: 35143607

Group type: EXPERIMENTAL
Intervention: REST intervention (occupational therapist‐led cognitive‐behavioral therapy for insomnia)
Number of subjects: 15
Study: 32963087

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy with shared airway view
Number of subjects: 36

Group type: COMPARATOR
Intervention: Videolaryngoscopy with covered screen
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Controlled environment and calm guidance
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intubations in stressful situations (delivery room, unstable infants, large audiences, parental presence)
Number of subjects: 36
Study: 35377261

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) paired with rehabilitation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 100